Dr. John Rogers from the University of Illinois at Urbana-Champaign has developed bioresorbable silicon electronics that can be used for real-time sensing of neural...
Dr. John Rogers from the University of Illinois at Urbana-Champaign has developed bioresorbable silicon electronics that can be used for real-time sensing of neural electrical activity. This invention could prevent follow-up neural surgeries, and has potentials for long-term monitoring of patients.
Dr. Andrew Smith from the University of Illinois has developed new quantum dots with a multidentate polymer coating that minimizes size while maintaining stability and...
Dr. Andrew Smith from the University of Illinois has developed new quantum dots with a multidentate polymer coating that minimizes size while maintaining stability and improving efficiency of conjugation. Quantum dots are promising agents for cellular and molecular imaging, but their bulky organic coatings have limited their use in cells. Dr. Smith's quantum dots are small, stable, and can be conjugated to targeting molecules and purified easily.
Dr. Hergenrother from the University of IL has developed a novel antibiotic that is effective against certain antibiotic-resistant gram-negative bacteria. His powerful...
Dr. Hergenrother from the University of IL has developed a novel antibiotic that is effective against certain antibiotic-resistant gram-negative bacteria. His powerful predictive algorithm determines accumulation of molecules in Gram-negative bacteria and enables conversion of known Gram-positive only antibiotics into novel compounds with Gram-negative potency.
Dr. Pan from the University of Illinois at Urbana-Champaign has developed a point of care device that can detect a penetrating ocular globe injury. Unlike current point of...
Dr. Pan from the University of Illinois at Urbana-Champaign has developed a point of care device that can detect a penetrating ocular globe injury. Unlike current point of care diagnostic tests for ocular globe injuries, which require a trained physician to subjectively identify a change in the color of a dye placed onto the ocular surface, the invention can be administered by a nurse or technician. This technology will allow for faster, cheaper, and more mobile means of diagnosing certain eye injuries.
This new class of nanobubbles for the treatment of hypoxia are comprised of FDA approved compounds and provide a biocompatible environment for incorporating pharmaceutical...
This new class of nanobubbles for the treatment of hypoxia are comprised of FDA approved compounds and provide a biocompatible environment for incorporating pharmaceutical agents. Moreover, unlike traditional phospholipid or dextran nanobubbles these new nanobubbles can release their payload without the use of an external trigger such as ultrasound. Additionally, these new nanobubbles have also shown significant promise as a therapy for Central Retinal Artery Occlusion (CRAO).